Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

168
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
168
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
152
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

354
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
354
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

213
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
213
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

167
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
167

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis.

Inflammatory bowel diseases·2026
Same author

Monocyte Distribution Width Differentiates Bacterial Enterocolitis from Acute Severe Ulcerative Colitis in the Emergency Department.

Digestive diseases and sciences·2026
Same author

An assessment of patient readiness to engage in digital patient reported outcomes in an Australian inflammatory bowel disease cohort.

Health informatics journal·2025
Same author

Editorial: Redefining Safety in Post-Liver Transplant IBD-Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply.

Alimentary pharmacology & therapeutics·2025
Same author

Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation.

Alimentary pharmacology & therapeutics·2025
Same author

Upadacitinib in Autoimmune Enteropathy-A Case Report.

Inflammatory bowel diseases·2025

Related Experiment Video

Updated: Jul 16, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K

Factors Associated With Response to Rescue Therapy in Acute Severe Ulcerative Colitis.

Christopher F D Li Wai Suen1,2, Dean Seah1, Matthew C Choy1,2

  • 1Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia.

Inflammatory Bowel Diseases
|September 19, 2023
PubMed
Summary

Predicting response to rescue therapy in acute severe ulcerative colitis (ASUC) is crucial. Factors like older age, infections, elevated C-reactive protein (CRP), and severe endoscopic findings indicate a higher risk of nonresponse to ASUC rescue therapies.

Keywords:
acute severe ulcerative colitiscolectomycyclosporininfliximabprognosis

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:21

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

172
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.1K

Related Experiment Videos

Last Updated: Jul 16, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:21

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

172
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.1K

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Clinical Research

Background:

  • Acute severe ulcerative colitis (ASUC) is a critical condition requiring colectomy if rescue therapy fails.
  • Predicting response to initial corticosteroid therapy is well-studied, but factors influencing rescue therapy outcomes need further investigation.
  • Understanding predictors of rescue therapy response is vital for improving clinical outcomes in ASUC patients.

Purpose of the Study:

  • To review existing evidence on factors associated with response to rescue therapy in adults with ASUC.
  • To identify clinical, hematological, biochemical, endoscopic, and pharmacological predictors of rescue therapy success or failure.
  • To highlight areas for future research to enhance predictive and prognostic models for ASUC.

Main Methods:

  • A systematic literature search was performed to identify relevant studies.
  • Two independent reviewers assessed the eligibility of retrieved records.
  • 101 studies were included in the final analysis, encompassing diverse predictive factors.

Main Results:

  • Forty-two factors associated with rescue therapy response were identified.
  • Older age (≥50 years), prior thiopurine use, and infections (CMV, C. difficile) predicted poorer response.
  • Biochemical markers (high CRP, low albumin) and severe endoscopic scores (Mayo 3, UC-ESI ≥5) were linked to worse outcomes.

Conclusions:

  • Specific factors can predict response to rescue therapy in ASUC, aiding clinical decision-making.
  • Integrating known and novel factors into predictive models can improve patient outcomes.
  • Further research is needed to define the roles of fecal calprotectin and infliximab drug levels in ASUC management.